Calvisken

Calvisken Brand names, Calvisken Analogs

Calvisken Brand Names Mixture

Viskazide 10/25tab (Hydrochlorothiazide + Pindolol)
Viskazide 10/50tab (Hydrochlorothiazide + Pindolol)

Calvisken Chemical_Formula

C₁₄H₂₀N₂O₂

Calvisken RX_link

http://www.rxlist.com/cgi/generic3/pindolol.htm

Calvisken fda sheet

Calvisken msds (material safety sheet)

Calvisken MSDS

Calvisken Synthesis Reference

No information avaliable

Calvisken Molecular Weight

248.321 g/mol

Calvisken Melting Point

167-171 ^oC

Calvisken H₂O Solubility

7880 mg/L

Calvisken State

Solid

Calvisken LogP

2.525

Calvisken Dosage Forms

Tablet

Calvisken Indication

For the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.

Calvisken Pharmacology

Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Calvisken Absorption

Rapidly and reproducibly absorbed (bioavailability greater than 95%).

Calvisken side effects and Toxicity

LD₅₀=263 mg/kg (orally in rats). Signs of overdose include excessive bradycardia, cardiac failure, hypotension, and bronchospasm.

Calvisken Patient Information

Calvisken Organisms Affected

Humans and other mammals